Sep 25, 2026, 5:00 PM EDT · 23 days ago Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
2026-09-17T13:35:50.000Z · 4 weeks ago Calidi prices 1.025M shares at $1.17 in registered direct offering
Sep 17, 2026, 9:10 AM EDT · 4 weeks ago Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Sep 8, 2026, 8:00 AM EDT · 5 weeks ago Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Aug 13, 2026, 4:30 PM EDT · 2 months ago Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Jul 27, 2026, 8:00 AM EDT · 2 months ago Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
Jul 21, 2026, 8:00 AM EDT · 2 months ago Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Jul 20, 2026, 4:30 PM EDT · 3 months ago Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Jul 8, 2026, 4:05 PM EDT · 3 months ago Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Jun 24, 2026, 8:00 AM EDT · 3 months ago Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Jun 23, 2026, 8:00 AM EDT · 3 months ago Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
2026-06-16T12:39:20.000Z · 4 months ago Calidi receives pre-IND regulatory feedback from FDA for CLD-401
Jun 16, 2026, 8:00 AM EDT · 4 months ago Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Jun 8, 2026, 8:00 AM EDT · 4 months ago Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
2026-05-26T15:37:20.000Z · 4 months ago Calidi announces online abstract acceptances at 2026 ASCO Meeting
May 26, 2026, 8:00 AM EDT · 4 months ago Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
May 22, 2026, 6:00 PM EDT · 4 months ago Calidi Biotherapeutics Provides Required NYSE American Disclosure
May 14, 2026, 4:10 PM EDT · 5 months ago Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
May 13, 2026, 8:00 AM EDT · 5 months ago Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
Apr 29, 2026, 8:00 AM EDT · 5 months ago Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
Apr 20, 2026, 8:00 AM EDT · 6 months ago Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Mar 27, 2026, 4:25 PM EDT · 6 months ago Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
2026-03-12T12:17:48.000Z · 7 months ago Calidi presents manufacturing process for CDI-401 at BioProcessing Summit
Mar 12, 2026, 8:00 AM EDT · 7 months ago Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing
Mar 9, 2026, 8:50 PM EDT · 7 months ago Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option
2026-03-06T13:35:48.000Z · 7 months ago Calidi prices 10.5M units at 50c in underwritten public offering
Mar 6, 2026, 8:30 AM EST · 7 months ago Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Feb 20, 2026, 8:00 AM EST · 8 months ago Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
2026-02-12T13:10:13.000Z · 8 months ago Calidi to present on approach to bispecific T-cell engagers using RedTail
Feb 12, 2026, 8:00 AM EST · 8 months ago Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
Nov 17, 2025, 8:00 AM EST · 11 months ago Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
Nov 13, 2025, 4:15 PM EST · 11 months ago Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
2025-11-10T13:20:35.000Z · 11 months ago Calidi presents new data on CLD-401 at 2025 SITC annual meeting
2025-10-30T12:15:32.000Z · 11 months ago Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting
Aug 21, 2025, 6:33 PM EDT · 1 year ago Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option
2025-08-20T13:20:27.000Z · 1 year ago Calidi prices 1.47M units at $2.00 in underwritten public offering
Aug 20, 2025, 9:15 AM EDT · 1 year ago Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Aug 8, 2025, 4:15 PM EDT · 1 year ago Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
2025-08-05T13:43:07.000Z · 1 year ago Calidi Biotherapeutics Inc trading halted, volatility trading pause
Jul 25, 2025, 4:45 PM EDT · 1 year ago Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Jul 22, 2025, 8:00 AM EDT · 1 year ago Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24
Jul 10, 2025, 8:30 AM EDT · 1 year ago Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
Jul 9, 2025, 2:01 PM EDT · 1 year ago Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Jul 8, 2025, 8:30 AM EDT · 1 year ago Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
Apr 16, 2025, 9:30 AM EDT · 1 year ago Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds EGLE FLAG
Mar 31, 2025, 4:30 PM EDT · 1 year ago Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Mar 28, 2025, 9:00 AM EDT · 1 year ago Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Mar 10, 2025, 8:00 AM EDT · 1 year ago Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
Feb 28, 2025, 9:00 AM EST · 1 year ago Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV OSTX
Feb 24, 2025, 8:00 AM EST · 1 year ago Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
Jan 29, 2025, 8:00 AM EST · 1 year ago Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5
Jan 28, 2025, 8:00 AM EST · 1 year ago Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
Jan 10, 2025, 4:30 PM EST · 1 year ago Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
Jan 10, 2025, 8:30 AM EST · 1 year ago Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
Nov 15, 2024, 4:05 PM EST · 1 year ago Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock